224 related articles for article (PubMed ID: 14872428)
1. Variants of recombinant factor VIIa with increased intrinsic activity.
Persson E
Semin Hematol; 2004 Jan; 41(1 Suppl 1):89-92. PubMed ID: 14872428
[TBL] [Abstract][Full Text] [Related]
2. A novel therapeutic approach combining human plasma-derived Factors VIIa and X for haemophiliacs with inhibitors: evidence of a higher thrombin generation rate in vitro and more sustained haemostatic activity in vivo than obtained with Factor VIIa alone.
Tomokiyo K; Nakatomi Y; Araki T; Teshima K; Nakano H; Nakagaki T; Miyamoto S; Funatsu A; Iwanaga S
Vox Sang; 2003 Nov; 85(4):290-9. PubMed ID: 14633255
[TBL] [Abstract][Full Text] [Related]
3. Prerequisites for recombinant factor VIIa-induced thrombin generation in plasmas deficient in factors VIII, IX or XI.
Livnat T; Zivelin A; Martinowitz U; Salomon O; Seligsohn U
J Thromb Haemost; 2006 Jan; 4(1):192-200. PubMed ID: 16409469
[TBL] [Abstract][Full Text] [Related]
4. Recombinant factor VIIa for patients with inhibitors to factor VIII or IX or factor VII deficiency.
Scharrer I
Haemophilia; 1999 Jul; 5(4):253-9. PubMed ID: 10469179
[TBL] [Abstract][Full Text] [Related]
5. The treatment of bleeding in hemophilic patients with inhibitors with recombinant factor VIIa.
Negrier C; Hay CR
Semin Thromb Hemost; 2000; 26(4):407-12. PubMed ID: 11092216
[TBL] [Abstract][Full Text] [Related]
6. The role of recombinant factor VIIa (FVIIa) in fibrin structure in the absence of FVIII/FIX.
He S; Blombäck M; Jacobsson Ekman G; Hedner U
J Thromb Haemost; 2003 Jun; 1(6):1215-9. PubMed ID: 12871322
[TBL] [Abstract][Full Text] [Related]
7. General haemostatic agents--fact or fiction?
Hedner U
Pathophysiol Haemost Thromb; 2002; 32 Suppl 1():33-6. PubMed ID: 12214145
[TBL] [Abstract][Full Text] [Related]
8. Potential role of recombinant factor VIIa as a hemostatic agent.
Hedner U; Erhardtsen E
Clin Adv Hematol Oncol; 2003 Feb; 1(2):112-9. PubMed ID: 16224390
[TBL] [Abstract][Full Text] [Related]
9. Dose optimization of recombinant factor VIIa for control of mild to moderate bleeds in inhibitor patients: Improved efficacy with higher dosing.
Abshire TC
Semin Hematol; 2004 Jan; 41(1 Suppl 1):3-7. PubMed ID: 14872413
[TBL] [Abstract][Full Text] [Related]
10. Enhanced in vitro procoagulant and antifibrinolytic potential of superactive variants of recombinant factor VIIa in severe hemophilia A.
Lisman T; de Groot PG; Lambert T; Røjkjaer R; Persson E
J Thromb Haemost; 2003 Oct; 1(10):2175-8. PubMed ID: 14521601
[TBL] [Abstract][Full Text] [Related]
11. Whole blood clot formation phenotypes in hemophilia A and rare coagulation disorders. Patterns of response to recombinant factor VIIa.
Sørensen B; Ingerslev J
J Thromb Haemost; 2004 Jan; 2(1):102-10. PubMed ID: 14717973
[TBL] [Abstract][Full Text] [Related]
12. Recombinant factor VIIa addition to haemophilic blood perfused over collagen/tissue factor can sufficiently bypass the factor IXa/VIIIa defect to rescue fibrin generation.
Li R; Panckeri KA; Fogarty PF; Cuker A; Diamond SL
Haemophilia; 2017 Sep; 23(5):759-768. PubMed ID: 28475272
[TBL] [Abstract][Full Text] [Related]
13. Pharmacological concentrations of recombinant factor VIIa restore hemostasis independent of tissue factor in antibody-induced hemophilia mice.
Keshava S; Sundaram J; Rajulapati A; Pendurthi UR; Rao LV
J Thromb Haemost; 2016 Mar; 14(3):546-50. PubMed ID: 26727350
[TBL] [Abstract][Full Text] [Related]
14. Effects of recombinant factor VIIa on platelet function and clot structure in blood with deficient prothrombin conversion.
Carr ME; Martin EJ; Kuhn JG; Seremetis SV
Thromb Haemost; 2003 May; 89(5):803-11. PubMed ID: 12719776
[TBL] [Abstract][Full Text] [Related]
15. Effect of activated recombinant human factor 7 (Niastase) on laboratory testing of inhibitors of factors VIII and IX.
Keeney M; Allan DS; Lohmann RC; Yee IH
Lab Hematol; 2005; 11(2):118-23. PubMed ID: 16024335
[TBL] [Abstract][Full Text] [Related]
16. Activated recombinant human coagulation factor VII (rFVIIa) therapy for abdominal bleeding in patients with inhibitory antibodies to factor VIII.
Liebman HA; Chediak J; Fink KI; Galvez AG; Shah PC; Sham RL
Am J Hematol; 2000 Mar; 63(3):109-13. PubMed ID: 10679799
[TBL] [Abstract][Full Text] [Related]
17. Improved hemostasis with superactive analogs of factor VIIa in a mouse model of hemophilia A.
Tranholm M; Kristensen K; Kristensen AT; Pyke C; Røjkjaer R; Persson E
Blood; 2003 Nov; 102(10):3615-20. PubMed ID: 12869500
[TBL] [Abstract][Full Text] [Related]
18. NovoSeven: mode of action and use in acquired haemophilia.
Von Depka M
Intensive Care Med; 2002 Oct; 28 Suppl 2():S222-7. PubMed ID: 12404090
[TBL] [Abstract][Full Text] [Related]
19. In vitro evidence of a tissue factor-independent mode of action of recombinant factor VIIa in hemophilia.
Augustsson C; Persson E
Blood; 2014 Nov; 124(20):3172-4. PubMed ID: 25232061
[TBL] [Abstract][Full Text] [Related]
20. Mechanism of action of factor VIIa in the treatment of coagulopathies.
Hedner U
Semin Thromb Hemost; 2006 Apr; 32 Suppl 1():77-85. PubMed ID: 16673269
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
